Nelson Alvis
University of Cartagena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nelson Alvis.
Vaccine | 2008
Sue J. Goldie; Mireia Diaz; Dagna Constenla; Nelson Alvis; Jon Kim Andrus; Sun Young Kim
Using population and epidemiologic data for 33 countries in Latin America and the Caribbean (LAC), a model-based approach estimated averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I
Salud Publica De Mexico | 2005
Saholeth Nájera; Nelson Alvis; David Babilonia; Ligia Alvarez; Salim Mattar
/DALY averted) for human papillomavirus (HPV) vaccination of young adolescent girls. Absolute reduction in lifetime cancer risk varied between countries, depending on incidence, proportion attributable to HPV-16 and 18, and population age-structure; for example, with 70% coverage, cancer reduction ranged from 40% in Mexico to more than 50% in Argentina. Screening of women over age 30 three times per lifetime, after vaccinating them as pre-adolescents, is expected to provide a relative increase of 25% to 30% in mortality reduction. Countries with the highest risk of cancer (age-standardized rate > 33.6) accounted for only 34% of deaths averted with vaccination, highlighting why a regional universal vaccination approach will be most effective in reducing the overall global burden. At I
Vaccine | 2010
Fernando de la Hoz; Nelson Alvis; J Narváez; natalia cediel; Oscar Gamboa; Martha Velandia
25 per vaccinated girl (
Revista Panamericana De Salud Publica-pan American Journal of Public Health | 2011
Elkin Lemos; Fernando De la Hoz Restrepo; Nelson Alvis; Elkin Quevedo; Oscar Cañon; Yazmin León
5 per dose), for all 33 countries, the cost per DALY averted is less than I
Revista de salud pública (Bogotá, Colombia) | 2007
Nelson Alvis; Salim Mattar; Jair Garcia; Edwin Conde; Alberto Román Padilla Díaz
400; at I
Revista de salud publica (Bogota, Colombia) | 2008
Francisco Buelvas; Nelson Alvis; Indira Buelvas; Jorge Miranda; Salim Mattar
10 (
Revista de salud publica (Bogota, Colombia) | 2006
Vaneza Tique; Nelson Alvis; Renata Parodi; Alvaro Bustos; Salim Mattar
2 per dose) the vaccine is cost saving in 26 out of 33 countries. For all countries, ratios become less attractive (i.e., increase) as the cost of the vaccine increases. For example, at current vaccine prices (
Revista Panamericana De Salud Publica-pan American Journal of Public Health | 2010
Nelson Alvis; Fernando de la Hoz; J Narváez
120 per dose), the cost per DALY averted is I
Infectio | 2010
Pedro Polo; Carlos Castañeda; María Sierra; Nelson Alvis
7,300 in Mexico, I
Revista Medica De Chile | 2010
Nelson Alvis; María Valenzuela
3,700 in Nicaragua, and I